Risankizumab versus apremilast in the era of skin clearance

Br J Dermatol. 2023 Nov 16;189(6):e101-e102. doi: 10.1093/bjd/ljad328.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Adult
  • Antibodies, Monoclonal*
  • Humans
  • Psoriasis* / drug therapy
  • Skin

Substances

  • risankizumab
  • apremilast
  • Antibodies, Monoclonal